Dermapharm H1 FY26 EBITDA jumps 27.3% to EUR 184.5 million; revenue rises 2.9% to EUR 591 million

• Dermapharm posted H1 2026 revenue up 2.9% to EUR 591 million; IFRS EBITDA jumped 27.3% to EUR 184.5 million.
• IFRS EBITDA margin widened 6 percentage points to 31.2%, reflecting EUR -21.3 million of non-recurring items in the period.
• IFRS adjusted EBITDA rose 10.3% to EUR 163.2 million; adjusted margin increased 1.8 percentage points to 27.6%.
• Branded pharmaceuticals delivered strong organic and acquisition-driven growth, cushioning planned reorganization expenses at axicorp and changes at Arkopharma.
• Management confirmed 2026 guidance for revenue of EUR 1.18-1.22 billion; adjusted EBITDA seen at EUR 331-341 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermapharm Holding SE published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2380076_en) on August 11, 2026, and is solely responsible for the information contained therein.